TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03404245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education, Fitbit/self-management app, physiotherapist counselling.
Description: Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Same intervention with a 6 month delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
Study: NCT03311555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg tablet daily for 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation
Description: ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy
Description: On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
Study: NCT02461212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
Study: NCT04189952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.
Study: NCT04371016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verticalization (bed)
Description: The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method
Study: NCT00315341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
Study: NCT02023827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAYS Intervention
Description: The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
Study: NCT00313872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP
Description: D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre \& Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre \& post hydration (if Mg \<WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
Study: NCT04189952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.
Study: NCT04142229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iAPS
Description: The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-Augmented Pump
Description: Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
Study: NCT04404127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab 20 milligram [Simulect]
Description: Basiliximab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: No-Induction
Study: NCT00735475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Virus Vaccine (Afluria®)
Description: A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Licensed Influenza Virus Vaccine (Fluzone®)
Description: A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
Study: NCT00662818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant
Description: Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant
Description: Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Paracetamol
Description: Acetaminophen/Paracetamol (500 mg X 2 dosage units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Paracetamol
Description: Acetaminophen/Paracetamol (500 mg X 2 dosage units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Telcagepant
Description: Placebo 300 mg soft gel capsules or placebo 280 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Telcagepant
Description: Placebo 300 mg soft gel capsules or placebo 280 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Acetaminophen/Paracetamol
Description: Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Acetaminophen/Paracetamol
Description: Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
Study: NCT00924118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
Study: NCT02184364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Klimadynon®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of Klimadynon®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Klimadynon®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oestrofeminal®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04369781

Intervention type: DIAGNOSTIC_TEST
Intervention: transcutaneous oxygen pressure recording at rest
Description: Recording of limb and chest transcutaneous oxygen pressure
Study: NCT04647552

Intervention type: DRUG
Intervention: Drug Steroid
Description: hydrocortisone injection
Study: NCT06444204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Rilzabrutinib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Rilzabrutinib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Rilzabrutinib tablet administered orally
Study: NCT02554227

Intervention type: OTHER
Intervention: Cytokine Profile and suPAR
Description: Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
Study: NCT03369327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir and daclatasvir
Description: Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:~1. Daclatasvir 30 mg and sofosbuvir 400 mg~2. Daclatasvir 60 mg and sofosbuvir 400 mg~3. Daclatasvir 90 mg and sofosbuvir 400 mg
Study: NCT04690894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block - caudal block
Description: the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block - caudal block
Description: the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered
Study: NCT01327443

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: Nutritional counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Under direct supervision
Study: NCT04184232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells
Description: Autologous dendritic cells primed with muc-1/wt-1 peptides

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of bladder cancer according to the Clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of bladder cancer according to the Clinical protocols
Study: NCT01026532

Intervention type: BIOLOGICAL
Intervention: Segmental Allergen Challenge
Description: Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
Study: NCT03803839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clodronate
Study: NCT03250273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
Study: NCT00978952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Large Diameter Advanta™ V12 Covered Stent
Description: Stent placement
Study: NCT02265523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Description: The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
Study: NCT01220570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus + Dalotuzumab
Description: Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
Study: NCT00116181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
Study: NCT01805661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canal Block and Capsular Injection
Description: Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral with Tibial Nerve Block
Description: Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
Study: NCT02262897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
Study: NCT03985683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: agility tests
Description: In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Interventional
Description: Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
Study: NCT00560729

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Renutryl 500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Generique

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Generique + Renutryl 500
Study: NCT01865357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI - Clinical and cognitive evaluation
Description: * Clinical evaluation (EDSS, MSFC)~* Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~* Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI - Clinical and cognitive evaluation
Description: * Clinical evaluation (EDSS, MSFC)~* Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~* Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye movement
Description: Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye movement
Description: Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
Study: NCT01505920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Description: 10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine submucosal injection
Description: 2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
Study: NCT03629288

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose tab
Description: Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
Study: NCT03373214

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1
Description: Na-GST-1/Alhydrogel®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1
Description: Na-GST-1/Alhydrogel®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1
Description: Na-GST-1/Alhydrogel®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPG 10104
Description: CPG 10104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPG 10104
Description: CPG 10104
Study: NCT04579809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 strand technique
Description: 4 strand technique reapir of tendin flexor injury

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 strand technique
Description: 4 strand technique reapir of tendin flexor injury
Study: NCT02507791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Charge HR plus weekly phone calls to review physical activity data
Description: Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Charge HR plus weekly phone calls to review physical activity data
Description: Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
Study: NCT04222920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose reduction to 2mg/L
Description: Adalimumab dose reduction aiming drug concentration of 2mg/L

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dose reduction to 5mg/L
Description: Adalimumab dose reduction aiming drug concentration of 5mg/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab